Literature DB >> 7065956

Corneal xerophthalmia and keratomalacia.

A Sommer, T Sugana.   

Abstract

Detailed examinations were conducted on 162 consecutive children with nutritional keratopathy. Surface changes ranged from mild haziness through generalized xerosis and formation of thickened keratinized plaques. Diffuse stromal edema occured early in the disease. Stromal loss took two forms: relatively small, sharply demarcated, eccentric, noninfiltrated cylindrical ulcers of varying depth; and localized or generalized, usually full-thickness necrosis. All forms of involvement were sometimes present in the same individual or even the same eye. Traumatic separation of a keratinized plaque, or decompensation of a dellen, accounted for some instances of stromal baring. In other cases, stromal melting appeared to progress below an intact epithelium. Focal areas of necrosis healed rapidly, as adherent leukomas; larger lesions sloughed, forming extensive descemetoceles. With therapy, the vast majority of children retained central corneal clarity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065956     DOI: 10.1001/archopht.1982.01030030406003

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Keratoplasty for keratomalacia in preschool children.

Authors:  R B Vajpayee; M Vanathi; R Tandon; N Sharma; J S Titiyal
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

2.  Bilateral Corneal Melting in a Pediatric Patient with Severe Vitamin A Deficiency: A Case Report and Review of Literature.

Authors:  Zabih Ur Rahman Roheen; Mirwais Saleh; Tawfiq Ahmad Mushkani
Journal:  Int Med Case Rep J       Date:  2022-05-03

3.  Mortality associated with mild, untreated xerophthalmia.

Authors:  A Sommer
Journal:  Trans Am Ophthalmol Soc       Date:  1983

4.  The decline of admissions for xerophthalmia at Cicendo Eye Hospital, Indonesia, 1981-1992.

Authors:  R D Semba; B Susatio; G Natadisastra
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.